Virtual care provider Teladoc Health (NYSE:TDOC) announced on Wednesday that it has agreed to acquire Catapult Health, a provider of virtual preventive care services for USD65m in cash, plus up to USD5m in additional earnout consideration.
The deal will strengthen Teladoc Health's integrated care strategy, which focuses on expanding membership, improving healthcare outcomes and advancing mental health services. Catapult Health's innovative VirtualCheckup wellness exam will enhance Teladoc Health's capabilities in preventive care and chronic care management.
Catapult Health's at-home diagnostic testing and high-touch engagement model will complement Teladoc Health's virtual care solutions. The acquisition will also facilitate the integration of Catapult Health's technology into Teladoc Health's care management programmes, including diabetes, hypertension and weight management.
As of the third quarter of 2024, Catapult Health's trailing 12-month revenue was approximately USD30m.
Following the acquisition, Catapult Health will operate within Teladoc Health's Integrated Care segment.
Subject to customary conditions, the acquisition is expected to close in the first quarter of 2025.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies